Mab A Case Study In Bioprocess Development | A

The A-Mab Case Study is a landmark industry document developed by the CMC Biotech Working Group to demonstrate the practical application of Quality by Design (QbD) principles to the development and manufacturing of monoclonal antibodies (mAbs). Unlike traditional "test-to-quality" approaches, this study illustrates how to "build quality into" a product through deep process understanding and risk management. 1. Core Concept: Quality by Design (QbD)

7. Conclusion

This case study demonstrates that a modern mAb process is not developed linearly. By integrating upstream media chemistry (clone #47B + metal modulation) with downstream flocculation and high-resilience Protein A capture, the team transformed a problematic, aggregate-prone mAb (initial yield <1.5 g/L recoverable) into a robust 6.1 g/L titer process with a 71% final recovery. The drug product met all Phase I release specifications for purity, potency, and safety.

The development of a monoclonal antibody (mAb) bioprocess is a complex and challenging task. Monoclonal antibodies are a class of therapeutic proteins used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. The bioprocess development of a mAb involves several critical steps, including cell line development, fermentation, purification, and formulation. In this case study, we will explore the bioprocess development of a model mAb, "A Mab," from cell line development to commercial-scale production. A Mab A Case Study In Bioprocess Development

• Upstream: pH shift → deamidated variants
• Downstream: Elution pH → aggregates
• Formulation: Polysorbate concentration → particle formation

Proposes methods for real-time release testing and lifecycle management to maintain consistent quality throughout commercial manufacturing. Relevant Resources Quality By Design for Monoclonal Antibodies, Part 1

Development begins with the Target Product Profile (TPP), which outlines the desired clinical performance. The study identified key attributes that must be controlled, including: The A-Mab Case Study is a landmark industry

, specifically aggregates and fragments, which threatened the stability and efficacy of the final therapeutic. The Solution: A Quality by Design (QbD) Approach Instead of traditional trial-and-error, the team utilized a QbD framework to identify Critical Quality Attributes (CQAs): Upstream Optimization: By fine-tuning the feed strategy

One critical insight: Routine HCP ELISA does not detect a specific CHO protein (Cathepsin D) that co-elutes with Mab-X during AEX. The team adds a secondary orthogonal method (LC-MS/MS) to verify HCP clearance. Proposes methods for real-time release testing and lifecycle

Fermentation